Redx Pharma Plc (REDX.L) LSE
15.00
+3.6(+31.58%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
Redx Pharma Plc
Address
Alderley Park
Macclesfield, SK10 4TG
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 16 2546 9900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
101
First IPO Date
March 27, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Lisa Mary Whewell Anson | Chief Executive Officer & Executive Director | 608,127 | 1968 |
| James Mead | Chief Operating Officer | 132,671 | 1978 |
| Caroline Phillips | Senior Vice President of Biology | 0 | N/A |
| Cliff Jones | Senior Vice President of Chemistry, DMPK & Intellectual Property | 0 | N/A |
| Karl Hard | Head of Investor Relations | 0 | 1962 |
| Richard Armer | Chief Scientific Officer | 0 | N/A |
| Craig Tilston | Head of Development Operations | 0 | N/A |
| Peter J. Collum | Chief Financial Officer | 0 | N/A |
| Caitlin Pearson | Head of Communications | 0 | N/A |
| Claire Solk | General Counsel & Company Secretary | 0 | N/A |
Description
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
